The DOI matches its Crossref record.
Prostate Cancer Specific Mortality and Gleason 7 Disease Differences in Prostate Cancer Outcomes Between Cases With Gleason 4 + 3 and Gleason 3 + 4 Tumors in a Population Based Cohort
Open accessAbstract
PURPOSE: Reports of biochemical recurrence after prostate cancer primary therapy show differences between Gleason 4 + 3 and 3 + 4 tumors. To our knowledge these findings have not been explored for prostate cancer specific mortality. In this population based cohort we determined prostate cancer outcomes at different Gleason scores, particularly the different Gleason 7 patterns. MATERIALS AND METHODS: Men 40 to 64 years old who were diagnosed with prostate cancer between 1993 and 1996 in King County, Washington comprised the cohort. Recurrence/progression was determined by followup survey and medical record review. Mortality and cause of death were obtained from the Seattle-Puget Sound Surveillance, Epidemiology and End Results registry. HRs for outcomes were determined by Cox proportional hazards regression analysis. RESULTS: In 753 men with prostate cancer 65 prostate cancer specific deaths occurred during a median followup of 13.2 years. The 10-year prostate cancer specific survival rate for Gleason 6 or less, 3 + 4, 4 + 3 and 8-10 disease was 98.4%, 92.1%, 76.5% and 69.9%, respectively. Compared to patients with Gleason 3 + 4 disease those with Gleason 4 + 3 tumors were at increased risk for prostate cancer specific mortality in the unadjusted and multivariate models (HR 2.80, 95% CI 1.26-6.18 and HR 2.12, 95% CI 0.87-5.17, respectively). In men undergoing curative therapy with radical prostatectomy or radiation therapy there was an increased risk of recurrence/progression (HR 2.10, 95% CI 1.08-4.08) and prostate cancer specific mortality (HR 3.17, 95% CI 1.04-9.67) in those with Gleason 4 + 3 vs 3 + 4 tumors in the multivariate models. No difference in prostate cancer specific mortality was seen between Gleason 4 + 3 and 8-10 tumors. CONCLUSIONS: Gleason 7 prostate cancer shows heterogeneous behavior with Gleason 3 + 4 and 4 + 3 tumors conferring different prostate cancer specific mortality. These data provide important information for counseling patients with Gleason 7 prostate cancer on the natural history of the disease and may inform treatment decisions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Epstein, J. I., Egevad, L., Amin, M. B., Delahunt, B., Srigley, J. R., & Humphrey, P. A. (2016) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000530 · Cited by 3,236
Fehr, D., Veeraraghavan, H., Wibmer, A., Gondo, T., Matsumoto, K., Vargas, H. A., Sala, E., Hricak, H., & Deasy, J. O. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505935112 · Cited by 382
Prostate cancer epidemiology in the United States
Brawley, O. W. (2012) · World Journal of Urology · doi:10.1007/s00345-012-0824-2 · Cited by 333
Qi, X., Karagoz, K., Ren, J., Foran, D. J., & Gatza, M. (2018) · Medical Imaging 2018: Imaging Informatics for Healthcare, Research, and Applications · doi:10.1117/12.2293193 · Cited by 11
Metadata
- Authors
- Wright, J. L., Salinas, C. A., Lin, D. W., Kolb, S., Koopmeiners, J., Feng, Z., & Stanford, J. L.
- Venue
- Journal of Urology
- Published
- 2009-12
- Volume
- 182
- Issue
- 6
- Pages
- 2702-2707
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2149403404
- Cited by
- 161
- References
- 0
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prostate Cancer Specific Mortality and Gleason 7 Disease Differences in Prostate Cancer Outcomes Between Cases With Gleason 4 + 3 and Gleason 3 + 4 Tumors in a Population Based Cohort. https://app.cochat.ai/papers/10.1016/j.juro.2009.08.026
- The paper
- Wright, J. L., Salinas, C. A., Lin, D. W., Kolb, S., Koopmeiners, J., Feng, Z., & Stanford, J. L. (2009). Prostate Cancer Specific Mortality and Gleason 7 Disease Differences in Prostate Cancer Outcomes Between Cases With Gleason 4 + 3 and Gleason 3 + 4 Tumors in a Population Based Cohort. Journal of Urology. https://doi.org/10.1016/j.juro.2009.08.026
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.